CClinicalTrials.gg
CompletedNCT01877174Updated Sep 3, 2014

MICHI™ Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study)

An observational study in Internal Carotid Artery Stenosis, sponsored by Silk Road Medical. Completed at 6 sites in 3 countries. Per ClinicalTrials.gov, last updated 2014-09-03.

Sponsored by Silk Road Medical · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
24
Sex
All
01

Study summary

This study will be conducted in up to 10 hospitals in Europe, up to 75 patients will be enrolled. The purpose of the study is to evaluate any debris that may be captured in the inline filter of the MICHI(TM) Neuroprotection System with Filter (NPS+f) during its use in a transcarotid stenting procedure. The MICHI NPS+f is an embolic protection device that uses reverse flow to protect the brain during stenting of the Internal Carotid Artery. It is CE marked and is used in routine practice for the purpose of this study.

02

Conditions studied

  • Internal Carotid Artery Stenosis

Browse trials for

Keywords

  • Internal Carotid Stenosis
  • Reverse Flow
  • Carotid stenting
  • MICHI(TM) NPS+f
03

In context

Carotid Stenosis

339 studies on the registry are indexed under Carotid Stenosis; 81 are open to participants now.

This study's enrollment of 24 is below the median of 173 across 144 observational studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

Silk Road Medical is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are booked for a routine stenting of the Internal Carotid Artery (bifurcation may be involved) using the MICHI(TM) NPS+f System, at vascular surgery departments or interventional radiology departments

Inclusion and exclusion criteria per CE marked Instructions For Use

Inclusion criteria

Inclusion Criteria:

  1. Adequate central venous access
  2. Common carotid artery reference diameter of at least 6 mm
  3. Carotid bifurcation is a minimum of 5 cm above the clavicle as measured by duplex Doppler ultrasound (DUS) or computerized axial tomography (CT) angiography or magnetic resonance (MR) angiography

Exclusion criteria

Exclusion Criteria:

  1. Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated
  2. Patients with unresolved bleeding disorders
  3. Patients with severe disease of the ipsilateral common carotid artery
05

Study design

Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MICHI(TM) NPS+f

    Patients routinely treated with the CE marked MICHI(TM) NPS+f System

    Device: MICHI(TM) NPS+f · Procedure: transcarotid stenting

Interventions

  • DeviceMICHI(TM) NPS+f

    Transcarotid delivery system for carotid stents with flow reversal

  • Proceduretranscarotid stenting
06

What researchers measure

Primary outcomes

  1. Percentage of patients with debris captured in the MICHI(TM) inline filter

    The percentage of patients with any debris captured in the MICHI(TM) inline filter will be calculated

    Time frame: During MICHI(TM) NPS+f procedure

Secondary outcomes

  1. Volume of debris captured in the MICHI(TM) inline filter

    For all patients, where debris is captured in the MICHI(TM) inline filter, the volume of debris will be measured

    Time frame: During MICHI(TM) NPS+f procedure

  2. Histological analysis of debris captured in the MICHI(TM) inline filter

    For all patients, where debris is captured in the MICHI(TM) inline filter, the type of plaque will be determined.

    Time frame: During MICHI(TM) NPS+f procedure

07

Study locations

6 sites
  • University Hospital
    Gent, 9000, Belgium
  • Augusta Krankenhaus
    Duesseldorf, 40472, Germany
  • University Hospital Son Espases
    Palma, Mallorca 07120, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Medico Quirurgic
    Jaen, 23007, Spain
  • Complejo Hospitalario de Toledo
    Toledo, 45004, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01877174
Lead sponsor
Silk Road Medical
Responsible party
Sponsor
First posted
Jun 13, 2013
Start date
May 2013
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Sep 3, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion